Subthalamic GAD gene therapy in a Parkinson's disease rat model

Science

Volumn 298, Issue 5592, 2002, Pages 425-429

  Luo, Jia ^a   Kaplitt, Michael G ^a   Fitzsimons, Helen L ^a   Zuzga, David S ^a   Liu, Yuhong ^a   Oshinsky, Michael L ^a   During, Matthew J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; DISEASES; ENZYMES;

NEUROTRANSMITTERS;

GENES;

4 AMINOBUTYRIC ACID; DOPAMINE; GLUTAMATE DECARBOXYLASE; VIRUS VECTOR;

GENE; NERVOUS SYSTEM DISORDER;

4 AMINOBUTYRIC ACID RELEASE; ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYST; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; ELECTROSTIMULATION; GENE THERAPY; GENE TRANSFER; MALE; NERVE CELL; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RAT; SOMATIC CELL; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINE; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; GAMMA-AMINOBUTYRIC ACID; GENE THERAPY; GENETIC VECTORS; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; HUMANS; IBOTENIC ACID; ISOENZYMES; MALE; MESENCEPHALON; MICE; MOTOR ACTIVITY; NERVE DEGENERATION; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHENOTYPE; RATS; STEM CELLS; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SYNAPTIC TRANSMISSION; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MAMMALIA; PARKINSONIA;

EID: 0037064165     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1074549     Document Type: Article

References (31)

1. J. A. Obeso et al., Neurology 55, S7 (2000).
2. P. C. Su et al., Ann. Neurol. 50, 514 (2001).
3. A. Benazzouz et al., Neuroscience 99, 289 (2000).
4. W. D. Hutchison et al., Ann. Neurol. 44, 622 (1998).
5. E. Rinvik, O. P. Ottersen, J. Chem. Neuroanat. 6, 19 (1993).
6. S. S. Gill, P. Heywood, Lancet 350, 1224 (1997).
7. L. Alvarez et al., Mov. Disord. 16, 72 (2001).
8. P. Limousin, Lancet 345, 91 (1995).
9. DBS Study Group. N. Engl. J. Med. 345, 956 (2001).
10. R. Levy et al., Brain 124, 2105 (2001).
11. Methods and other supporting material are available on Science Ontine.
12. M. G. Kaplitt et al., Nature Genet. 8, 148 (1994).
13. R. L. Klein et al., Exp. Neurol. 176, 66 (2002).
14. M. Mastakov, K. Baer, R. M. Kotin, M. J. During J. Virol. 76, 8446 (2002).
15. H. Niwa, K. Yamamura, J. Miyazaki, Gene 108, 193 (1991).
16. J. E. Donello, J. E. Loeb, T. J. Hope, J. Virol. 72, 5085 (1998).
17. M. J. During, K. Ryder, D. D. Spencer, Nature 376, 174 (1995).
18. H. L. Fitzsimons, J. Luo, M. J. During, data not shown.
19. Y. Smith, A. Parent, Brain 453, 353 (1988).
20. F. Hefti, E. Melamed, B. J. Sahakian, R. J. Wurtman, Pharmacol. Biochem. Behav. 12, 185 (1980).
21. J. M. Henderson et al., Eur. J. Neurosci. 11, 2749 (1999).
22. D. Young, P. A. Lawlor, P. Leone, M. Dragunow, M. J. During, Nature Med. 5, 448 (1999).
23. B. Piallat, A. Benazzouz, A. L. Benabid, Eur. J. Neurosci. 8, 1408 (1996).
24. N. Nakao, E. Nakai, K. Nakai, T, Itakura, Ann. Neurol. 45, 640 (1999).
25. G. A. Carvalho, G. Nikkhah, Exp. Neurol. 171, 405 (2001).
26. Y. Cao et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9844 (1996).
27. R. S. Sloviter et al., J. Comp. Neurol. 373, 593 (1996).
28. C. Schwarzer, G. Sperk, Neuroscience 69, 705 (1995).
29. M. Esclapez, C. R. Houser, J. Comp. Neurol. 412, 488 (1999).
30. T. Wichmann, M. A. Kliem, M. R. DeLong, Exp. Neurol. 167, 410 (2001).
31. We thank A. Tobin for the GAD65 and GAD67 cDNAs. We thank members of the During lab, especially S. Raniga for helpful discussions and technical assistance. The New Zealand Health Research Council, Marsden Fund, and New Economy Research Fund supported this work. M.J.D. and M.G.K. are members of the scientific advisory board and consultants for Neurologix Inc., a gene therapy company. Their activities have been fully disclosed and are being managed in accordance with their respective universities' conflict-of-interest policies.